Highlights
- 1PLoS pathogens · 2024
- 2Molecular cancer research : MCR · 2025
- 3Blood cancer journal · 2026
Publications
Funding
Active
12 grants- MPIConsortium for Advancing Management and Prevention of Cancer in People with HIV - RESOURCE LABNational Cancer Institute · 2015–2030 · via EMMES Corporation· 7 renewalsUM1CA121947-19
- MPIWeill Cornell Initiative for Maximizing Student DevelopmentNational Institute of General Medical Sciences · 2024–2030TrainingT32GM152396-01
- MPITri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)National Institute of Allergy and Infectious Diseases · 2023–2028R38AI174255-01
- Co-ITranslating molecular profiles into treatment approaches to target disparities in lymphomaLeukemia & Lymphoma Society · 2024–2027 · via Emory UniversityLLS 7038-25
- KPTargeting Unmet Needs For B-cell LymphomasLeukemia & Lymphoma Society · 2022–2027LLS 7027-23 Project 1
- MPIB cell determinants of EBV latencyNational Cancer Institute · 2022–2027· 2 renewals
- Sub-PIRapid Sample to Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETENational Cancer Institute · 2022–2027 · via Cornell University - IthacaU01CA269199-04
- MPIRegulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in LymphomaNational Cancer Institute · 2021–2027 · via Northwell Health· 2 renewalsR01CA260691-04
- PIProject: Next-Gen Oncopathology Program - Charles NgMemorial Sloan Kettering Cancer Center · 2025–2026MSKCC 260282-01
- Co-IEpigenetic basis and therapeutic targeting of the unique lymphoma immunological nicheNational Cancer Institute · 2024–2026P01CA272295-02
- PI(PQ 6) New Models of KSHV Oncogenesis and KS Immune EnvironmentNational Cancer Institute · 2020–2026· 2 renewalsR01CA250074-05
Completed grants (29)
- PIRole of novel onco-histone mutations in B-cell malignanciesNational Cancer Institute · 2019–2025R01CA234561-05
- MPIWeill Cornell Initiative for Maximizing Student DevelopmentNational Institute of General Medical Sciences · 2019–2025R25GM130494-05
- KPDefining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse modelsStarr Cancer Consortium · 2022–2024I15-0016
- MPIEarly Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings Using KS-DetectNational Cancer Institute · 2016–2023 · via Cornell University - IthacaUH3CA202723-06
- KPCohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cellsAmerican Society of Hematology Inc · 2022–2023ASH 220412-01
- MPIRole Of The Linker Histones H1 In LymphomasAmerican Association for Cancer Research · 2021–2023FellowshipAACR 212713-01
- Co-IModulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To ImmunotherapyAmerican Society of Hematology Inc · 2021–2023ASH 210413-01
- KPTargeting Unmet Clinical Needs for B-Cell LymphomaLeukemia & Lymphoma Society · 2016–20217012-16 CORE A
- KPRational Translation of EZH2 Targeted Therapy in Germinal Center B-Cell LymphomaNational Cancer Institute · 2017–2021CareerK08CA219473-04
- PIDefining the Cellular Oncogenome of Kaposi SarcomaNational Cancer Institute · 2017–2021R21CA206851-02
- Co-IModulation of Viral Latency in EBV-Associated Lymphomas as a Mechanism to Sensitize Tumors to EBV-Directed Cellular TherapyStarr Cancer Consortium · 2018–2020I11-0043
- PINucleoside Analogue Selectively Activated by Adenosine Kinase to Treat ADK-expressing AdenocarcinomasDaedalus Fund for Innovation (Weill Cornell) · 2017–2020DFI 180572-02
- PIHHV-6 in the Lymphoma MicroenvironmentHHV-6 Foundation · 2019–2020HHV 200848-01
- PIService Agreement: Between WCM (PI Ethel Cesarman) and Fred Hutch (PI Warren Phipps) - Reference Grant: R21 CA206851Fred Hutchinson Cancer Research Center · 2017–2020ContractSA 183504-03
- PIThe 22nd International Conference on Kaposi's sarcoma-associated herpesvirus and Related AgentsNational Cancer Institute · 2019–2020R13CA239650-01
- PIElucidating the Etiologic Role of Linker Histone Mutations in Hematological MalignancyStarr Cancer Consortium · 2016–2019I9-A9-062
- Co-ITargeting Metabolism in Plasma Cell Neoplasms Using a Nucleoside AnalogLymphoma Research Foundation · 2017–2019FellowshipLRF 17020210-01
- MPIAIDS Clinical Trials Group (ACTG): A5178: Liver Disease ProgressionNational Institute of Allergy and Infectious Diseases · 2013–2018 · via The Brigham & Women's Hospital INC· 2 renewalsUM1AI068636-12
- KPTargeting the Hsp90 Oncoproteome in Pediatric Burkitt LymphomaSt. Baldrick's Foundation · 2015–2018SBF 170821-03
- PITargeting vFLIP for the Treatment of KSHV-Associated MalignanciesNational Cancer Institute · 2011–2018
- PIImmunology and Microbial Pathogenesis Research Training ProgramNational Institute of Allergy and Infectious Diseases · 2010–2016Training
- Sub-PISolar-Thermal PCR Assay for the Diagnosis of Kaposi's Sarcoma in Limited Resource SettingsNational Institute of Biomedical Imaging and Bioengineering · 2013–2015 · via Cornell University - IthacaR21EB016803-02
- MPIAIDS Malignancies Clinical Trials ConsortiumNational Cancer Institute · 2010–2015 · via EMMES CorporationU01CA121947-04
- Sub-PIKS-Detect: A Solar-Powered and Smartphone Integrated Instrument for Point-of-Care Diagnosis of Kaposi's SarcomaNational Cancer Institute · 2015–2015 · via A'as, Inc.R43CA193096-01
- MPIHIV-Associated Malignancy Research Pilot ProjectsNational Cancer Institute · 2010–2014 · via Sloan-Kettering Institute for Cancer Research· 2 renewals
- PIIdentifying small molecule inhibitors of KSHV vFLIP-TRAF2 interactions.NCI · 2006–2008 · via NIH RePORTERR21CA121934-02
- PIKSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMANCI · 1999–2003 · via NIH RePORTERR01CA082037-03
Honors & distinctions
- Member · American Society for Clinical Investigation · 2001
- Member · Association of American Physicians
Available technologies
- 6-Ethylthioinosine for the Treatment of Cancers that Overexpress Adenosine Kinase (ADK)6918Application filedPoC DataPMID 28504647
News mentions
- Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better DiagnosticsApril 24, 2026
For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.”
- Weill Cornell Medicine Wins Seventh Straight HEED Award for Diversity and InclusionNovember 12, 2024
Weill Cornell Medicine has been awarded the Health Professions Higher Education Excellence in Diversity (HEED) Award by INSIGHT Into Diversity magazine, for the seventh consecutive year.
- NIH Grant Will Support Lymphoma ResearchAugust 15, 2024
Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.
- Weill Cornell Initiative Continues to Bolster Diversity in Doctoral ProgramsApril 16, 2024
Cinthia Garcia was always passionate about science and medicine. The first in her family to complete post-secondary...
- Weill Cornell Initiative Nurtures Doctoral Students' Leadership, Community Engagement SkillsApril 16, 2024
Launched in 2019, the IMSD Program provides access to training that will enhance doctoral students’ leadership potential and meaningful community involvement.
Show 3 more mentions
- Weill Cornell Medicine Awarded NCI Grant For EBV-Related Lymphoma ResearchFebruary 23, 2023
Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute, part of the National Institutes of Health, to investigate the molecular mechanisms by which immune cells called B cells interact with Epstein-Barr virus (EBV) to cause lymphoma, particularly in people living with HIV.
- Inaugural Mastercard Pilot Grant Program Recipients SelectedApril 6, 2022
Five Weill Cornell Medicine faculty members have been awarded research funding from the Pilot Grant Program of the Mastercard Diversity-Mentorship Collaborative at Weill Cornell Medicine.
- Scientists Discover a Key Genetic Driver of LymphomasDecember 9, 2020
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
Mentoring
- JMJez MarstonMD-PhD WGS Immunology & Microbial Pathogenesis (MD-PhD)
- APAntonin PapinPostdoc mentee · 2020–2023
- JAJulio AlvarezMD mentee · Class of 2020
External relationships
Professional Services
Fred Hutchinson Cancer Center
Proprietary Interest
Center for Technology Licensing at Cornell University
Other
Genzyme Corporation